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1. Introduction
Spinal cord injury is the most devastating neural injury associated with road traffic accidents
or fall from height. Due to the compact arrangement of nerve fibers injury often leads to
significant deficits. In addition the cellular components of the spinal cord are highly susceptible
to injury. Together with the brain the ability of self-repair in comparison to other tissues of the
body is poor.[1]. Recently it is noted that the tissue response of the spinal cord to injury is
distinctly different from that of brain. The structure, cellular arrangement, vascularity, blood
spinal cord barrier, and lack of exposure to inflammatory cells are some of the limiting factors
for repair. Added to it receptor and membrane specializations that allow chemical and
electrical neuro transmission is prone to major ionic shifts. Though regeneration of spinal cord
in teleost fishes and urodele amphibians is established, no adult mammal is able to regenerate.
Hence, any insult can result in permanent and significant loss of body function. The therapies
currently practiced (surgery, drugs, rehabilitation), are grossly inadequate. The available
surgical treatment could only achieve prevention of further injury, maintain and support blood
flow, relieve the compression and secure stabilization of spine for early mobilization and
rehabilitation. Thus any new treatment for spinal cord injury that enables recovery of function
is the need of the hour and could be a significant advancement in clinical care. Biological
therapies are now being developed to augment the endogenous repair capabilities. They are
aimed at preservation of tissue, promotion of cell survival, activation of neuronal regrowth,
reduction in growth inhibition, scarring and cavitation, promotion of myelin repair thus
enhancing neuronal circuits.
We have studied and evaluated such applications to attempt spinal cord regeneration. Adult
human mesenchymal stem cells were the obvious choice due to their self-renewal property,
ease of availability, hypo-immunogenic property, non-teratogenicity, multi-potentiality with
high genetic stability.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Incidence
More than half of all spinal cord injuries occur in the cervical area; and a third of them affect
thoracic region. And the rest afflicts lumbar region. Most of the affected ones are young, in
their teens or twenties.. The leading causes of acute spinal cord injury include vehicular
accidents-41%, violence-22%, falls-21% and sports-8% [2]. Population studies shows the
incidence that vary between 2-20%. The official figure is 12% majority being, due to trauma.
The total number of people suffering a spinal cord injury in the US alone is 200,000; and 11,000
being added annually. The United Kingdom had over 700 new spinal cord injuries in 2004
(according to the International Campaign for Cures of Spinal Cord Injury).
Spinal cord injury (SCI) is the third most prevalent disease in our country after diabetes and
myocardial infarction. More than 12% of the Indian population suffers from the complications
associated with spinal cord injury and at least 10,000 are being affected annually [3]. Majority
are in the age group 21-36 years, the most productive years of life and 10-12% of severe head
injuries are associated with spinal injury. Awareness of this fact is important to protect spine
during pre hospital care. The clinical dictum is to suspect spinal injury in all high speed
injuries.. Penetrating injuries are relatively rare.
3. Pathophysiology
The biological response to spinal cord injury is customarily categorized into 3 phases that
follows a distinct but somewhat overlapping temporal sequence: acute or primary (seconds to
minutes after the injury), secondary or sub-acute (minutes to weeks after the injury), and
chronic (months to years after the injury) [4] Table 1. Primary injury is due to direct impact,
damaging the neurons, cell membranes, disrupting blood supply, and destabilizing the spinal
column. Secondary damage soon follows causing oedema, inflammation and free radical
production. A series of molecular changes then produce a cascading effect with liberation of
toxins compounding the primary injury. This can continue for few days to even up to six
months. [5,6,7] Diverse type of cells and molecules from nervous, immune and vascular system
are known to be involved in each phase. Most of the involved cells reside within the spinal
cord; also some other cells are recruited through the circulatory system [8]. Hypotension and
hypoxia can induce secondary permanent damage.
The onset of acute phase begins within seconds after an insult to spinal cord injury and is
marked by both local and systemic events. Cascade of sequential pathological changes can
occur during this phase. Local events such as cord compression, release and accumulation of
various neurotransmitters such as catecholamines and excitotoxic amino acids to a toxic level
enough to kill neural cells have been postulated to occur within seconds of injury [8]. Soon
after trauma, hypotension, shock, low cardiac output and respiratory failure and hypoxia occur
due to autonomic system failure. Between 15 to 30 minutes of post trauma, edema in white
matter and hemorrhage in gray matter have been reported. Electron microscopic studies
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revealed accumulation of intra-and extracellular fluids in the intercellular space. Ischemia or
local anemia has been reported within first few hours after severe trauma using angiographic
methods. A major reduction in spinal cord blood flow and lack of perfusion has been observed.
This ischemic zone encompasses a large portion of gray matter and surrounding white matter.
The main reasons postulated for ischemia are vasospasm (due to vasoconstrictors and
vasoactive amines), thrombosis, and platelet aggregation and hemorrhage [9]. By 4th hour,
axonal degeneration followed by vesicular disruption in myelin sheaths and ischemia becomes
evident. In other patients who do survive the initial injury, hyperaemia and other vascular
changes become prominent in 12 to 24 hours. These reactions are mediated through prosta‐
glandins, catecholamines and other agents [10]. At the end of 24 hours, necrosis starts and
remains active for another 24 hours which triggers the inflammatory response and disruption
of cell membranes resulting in release of intracellular contents of neurons and endothelial cells
lining them. This progressive, coagulative and patchy necrosis generally occupies the previous
hemorrhagic region and develops infarcts. Increased intracellular calcium influences enzymes,
such as phospholipases and phosphatases, to promote the breakdown of the cell membrane.
This results in liberation of free fatty acids, which are converted to prostaglandins which
Primary events
(0-2 hrs)
Secondary events
(1-6 hrs)
Spinal shock
(12 hrs –3 weeks)
Post spinal shock
Reflexes reappear
Mechanical
compression of
neural elements by
bone fragments,
disc material, and
ligaments,
laceration, shear
and distraction
1. Toxic metabolites
2. Electrolyte loss
3. Hypoperfusion of gray matter
4. Loss of autoregulation and
microcirculation
5. Vasospasm, thrombosis and
hemorrhage.
6. Accumulation of neurotransmitters :
like Glutamate leading to excitotoxicity
7. Elevated calcium levels
8. Cell membrane disruption and loss of
cell integrity
9. Cytotoxicity/free radicals/apoptosis/
prostaglandin release and lipid
peroxidation
10. Demyelination
11. Edema
12. Invasion of glial cells and activation of
resident microglial cell population.
1. Neurogenic shock.
2. Respiratory distress.
3. Impaired autonomic
functions.
4. Quadriplegia.
5 Anesthesia below
affected level.
6. Delayed gastric
emptying.
7. Paralytic ileus
1. Superficial abdominal
reflex
2. Criemasteric reflex
3. Bulbocavernous
reflex
4. Withdrawal reflex
5. Beevar sign etc
Table 1. Illustrates the different phases of spinal cord injury and the cascade of events associated with it.
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further increases the constriction of the blood vessels (vasospasm), which in turn contributes
to final cell death [11].
The secondary mechanisms are still ill understood. In literature( shows) there are approxi‐
mately  25  well  established  secondary  injury  mechanisms  are  described  [12,  13].  Secon‐
dary  phase  sets  in  minutes  and lasts  from days  to  months.  Some classical  examples  of
secondary injury mechanisms are continuation of events from the acute phase as outlined
by Charles. They are vasospasm, cell death from direct insult, ischemia, edema, derange‐
ments in ionic homeostasis and accumulation of neurotransmitters. In addition some novel
features,  marks the secondary phase such as  free-radical  production,  lipid peroxidation,
nitrous  oxide  excess,  conduction  block,  excess  noradrenaline,  energy  failure  and  de‐
creased ATP, immune cells invasion and release of cytokines, inflammatory mediated cell
death, neurite growth-inhibitory factors (Nogo-A, Rho-A, oligodendrocyte myelin glycopro‐
tein  (OMgp)  myelin-associated,  glycoprotein  (MAG),  and  chondroitin  sulfate  proteogly‐
cans, central chromatolysis,). vertebral compression / column instability, demyelination of
surviving axons, initiation of central cavitation, astroglial scar launch, plasma membrane
compromise  /permeability,  mitochondrial  malfunctions  and  activation  of  death  signals
causing apoptosis [8] are the remaining..
The third phase (chronic phase), along with the events in secondary phase, such as demyeli‐
nation, apoptosis, central cavitation, glial scar formation, is marked by the emergence of new
types of pathologies both at micro and macro level [8]. At microlevel, death of oligodendro‐
cytes, susceptible to Reactive Oxygen Species (ROS), loss of electrical impulse conduction by
axons due to demyelination and altered neurocircuits and alteration of ion channels and
receptors occur [9]. At macrolevel, formation of the glial scar represents an attempt by Glial
cells to contain the injury site and promote healing. In addition to reactive astrocytes, scar
formation also involves oligodendrocyte precursor cells, microglia, and macrophages. The
pathobiology of glial scar is due to reactive gliosis and extra cellular matrix (ECM) remodeling
[8]. These changes during reactive astrogliosis have the potential to alter astrocyte activities
both through gain and loss of functions that could be beneficial as well as detrimental to
surrounding neural and non-neural cells [16, 17, and 18].
More than a quarter of spinal cord injured patients develop cavities which eventually lead to
Syringomyelia [19]. Pathogenesis of post traumatic syrinx is not clear. Widely accepted theory
recognized two steps in the pathogenesis, namely formation of cavity followed by its enlarge‐
ment and extension. Microscopic examination demonstrated gliosis, which is an astrocytic
response to adjacent tissue damage, appears as high MRI signals around the syrinx. [20]. The
intial cystic lesion results from multiple factors like mechanical damage, local ischemia [19],
arterial and venous obstruction, liquifaction of hematoma, by lysosomal and other intracellular
enzymes [21].
Beside, chronic phase also initiates number of neuroprotective and regenerative responses.But
they are insufficient for regeneration of the nerve root by Schwann cells or oligodendrocytes.
Some compensation by spared neurons (sprouting) often with inappropriate connectivity.
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Finally the reactive astrogliosis itself hinders the axonal regrowth and the functional recovery
of the injured spinal cord [22].
3.1. Impediments for regeneration
Cord tissue comprises of several components with variable sensitivity to injury.[1].Injury often
causes cavitation of epicenter due to cell death, ischemia, mechanical injury, exitotoxicity and
neuro inflammation. This cavity can enlarge extending the injury up and down. In addition it
becomes a physical barrier for regeneration and cell transmission and cell migration. Body
attempts to contain the injury and promote healing resulting in gliosis. This astrocytic gliosis
becomes an impediment to the growth of axon described by Raymon Y Cajal in 1928 [1]. These
gliotic cells also secrete inhibitory molecules for the axonal growth and connectivity. Inflam‐
mation slows down the initial angiogenesis response and oligodendrocytes (secrete Nogo
molecules), glycoproteins Semaphoring 4D and Epherin B3,also have been shown to have
inhibitory role.[21,22,23]
4. Tools for assessing spinal cord injury and repair
4.1. Molecular, genetic, and in vitro tools
Techniques now have been developed that allow researchers to isolate and grow popula‐
tions of neurons to investigate the effects of specific proteins and molecules on neuronal
injury and repair. Neurons can be grown in isolation or with glial cells such as oligodendro‐
cytes or Schwann cells to study the processes of axonal outgrowth and myelination using
DNA or protein analysis. Furthermore, the elucidation of the signaling pathways responsi‐
ble for this switch in response may lead to the discovery of a strategy for enhancing axon
regeneration.
Often, in vitro assays are tested along with animal models which allow better understanding
of the effects detected in vitro and to be validated in a more complex system. The best studied
example includes chondroitin sulfate proteoglycans, a potent inhibitor of neurite outgrowth
in in vitro experiments. Analysis with animal models demonstrated that the levels of these
proteoglycans are enhanced, or up-regulated, during central nervous system (CNS) injury and
led to the development of a strategy to break down these substances and promote the regrowth
of axons in the intact rat spinal cord after an injury [21].
4.2. Animal models for spinal cord injury
No single  animal  model  has  dominated for  research in  this  area.  Two broad classes  of
models have accounted for the great majority of studies.  Both involve surgical exposure
of the cord.  Most commonly used models are transection or partial  injuries for detailed
studies of regeneration and experimental contusion and compression. Allen’s weight drop
model,  the  oldest  method in  use  and produced by  dropping a  known weight  onto  the
dorsal  side of  the exposed spinal  cord.  This  is  mainly to address the early processes of
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injury.  Besides  the  above  mentioned  category,  microlesion  formation  and  transgenic
models,  [25]  Photochemical  SCI  model,  excitotoxic  spinal  cord  injury  have  also  been
developed in recent years [26].
During the last two decades, various researchers have shown interest in developing variety of
animal models based on the above two categories, that mimic different attributes associated
with spinal cord injuries. Depending upon the purpose of the study and the specific aspect of
the injury to be investigated, researchers determine which animal model most closely repli‐
cates the injury in humans. Commonly used animal models for the investigation includes [8]
Primates – to test the safety and efficacy of the therapy, [9] Cat – to examine and define spinal
cord circuitry, [10] Mouse and rat – mainly used for the investigations of molecular, genetic
and anatomical response to injury and to modify genes to test the effect of restoration or loss
of function.
The kind of inquiries currently in focus can be addressed with rodent models, for which the
maximum number of biological reagents and tools are available. In time, there may be a need
to examine the conclusions of rodent studies in other models, to deal with questions of species
differences (biological responses, chromosomal arrangements, genetic variability and the
spatial arrangement of the nerve tracts) and mechanical scale (animal size, limited number of
animals for experimentation) and ethics [9].
5. Assessing SCI and repair mechanisms
5.1. Conventional treatment strategies
Treatment  for  Spinal  cord  injury  starts  at  the  site  of  accident  or  trauma.  Manual  spine
immobilization  or  using  cervical  collar  and  spine  board,  followed by  administration  of
analgesics to reduce pain is an established practice to achieve comfort to the patient. Careful
monitoring of airway, respiration, and arterial pressure is essential. Hypotension, hypoxia
are deleterious and should be avoided at all cost. From the scene of trauma, the patient is
moved to the medical center and assessed further with neurological status and clinical level
of injury. Base line clinical status is established and documented. In parallel other system‐
ic  injuries  were  also  evaluated.  ASIA  impairment  scale  modified  BENZEL  scale  and
FRANKEL scales are commonly used to evaluate progress.  MRI is  the gold standard in
imaging to  delineate  the  anatomy of  injury.  In  addition,  size  and extent  of  cord contu‐
sion, hemorrhage and edema have prognostic significance. Throughout its mandatory to
avoid secondary insults to spinal cord. Several drugs have been tried with no demonstra‐
ble benefit.  There is  no role for  steroids and Methylprednisolone.  All  attempts of  direct
surgical repair of spinal cord have failed.
5.2. Experimental strategies
Almost every aspect of the management of SCI is controversial, due to lack of good-quality
evidence. Currently all the modes of the experimental therapy falls into any of the following
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categories: neuroprotection, repair/regeneration, enhancing the plasticity and replace/assist
function. The details of all can be found at ICORD website (http://icord.org/).
5.3. Neuroprotection (randomized clinical trials)
Clinical trials should augment the neurological recovery data with outcome measures
designed to assess the functional significance of the neurological recovery. To date more than
70 clinical trials have been done on functional recovery of Spinal Cord Injury with drugs and
other therapeutic intervention (http://clinicaltrials.gov/). Of those, drugs which have direct
application in treatment regimen for SCI and the reason for their pitfalls are discussed here.
1. Pharmacological therapy
The first and extensive studied drug is Methyl prednisolone sodium succinate (MPSS), an anti
inflammatory corticosteroid exerting its function as antioxidant, enhancer of spinal cord blood
flow, by reducing calcium influx, posttraumatic axonal die back and attenuating lipid perox‐
idation. The drawback of this drug is that it did not rescue neurons from cell death and [16]
its high rates of adverse events such as the occurrence of pulmonary and gastrointestinal
complications and others. [8, 9, 15].
A noncompetitive N-methyl-d-aspartate receptor antagonist, gacyclidine (GK-11), showed
promise as a neuroprotective agent as evidenced by walking recovery, motor performance,
attenuation of spinal cord damage, reducing apoptosis of oligodendrocytes via inhibition of
proNGF production in microglia [18] etc, in rat model. However, this agent is no longer being
pursued for SCI [11] and the use of minocycline following contusion of cord requires further
investigation before clinical trials are implemented [17].
Minocycline, an antibiotic and anti-inflammatory substance facilitated overall motor recovery
and attenuated mechanical hyperalgesia in a rat model [8], but did not increase the survival
of the preganglionic parasympathetic neurons (PPNs) [20].
2. GM-1(Sygen), a ganglioside found in the neuronal cell membranes, was found to promote
recovery in a number of animal models. In human trials it resulted in statistically signif‐
icant improvement in ASIA motor score but failed to demonstrate a significant difference
in its primary outcome measure, a 2-point improvement on the modified Benzel walking
scale [8, 9].
3. Erythropoietin, a potent cytokine [25], and its analogues have been thoroughly investi‐
gated [26] and shown to protect neuronal cell in vitro from apoptosis and also suppress
the up-regulated expression of TGF-β [27, 25] reduces the inflammation, and restores the
vascular integrity [21].
4. Immunomodulatory treatment
Inflammatory processes that occur at the injury site of the spinal cord are both beneficial and
harmful. Phagocytic macrophages have been indicated in secondary destruction of neural
tissue post SCI [28; 29] but are not sufficient as compared with peripheral nerve injury.
Rapalino et al., [30], has demonstrated that implantation of activated macrophages in the site
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of injury in adult injured rats results in partial recovery. On the contrary, Popovich et al., [31]
suggested that depletion of macrophages may result in preservation of myelinated axons and
functional recovery following injury. A phase I clinical trial demonstrated the safety of
autologous macrophage transplantation into the damaged spinal cord within 14 days of injury.
5. Neurotrophic factors: Neurotrophic factors have been documented to improve cell
survival and axonal regeneration and various approaches have been developed to deliver
these factors to the site of injury. Stem cells from different sources like bone marrow [32,
33, adipose tissue, dental pulp [34], Wharton’s jelly, olfactory ensheathing cells [35], neural
stem cells [36] and embryonic stem cells [37] when transplanted in vivo have shown
significant recovery.
6. In a controlled double-blinded study, 20 patients receiving thyrotrophin releasing
hormone treatment showed significantly higher motor, sensory, and Sunnybrook scores
than placebo treatment. But because of patients lost to subsequent follow-up, data were
not highly informative [18]. Another study in rats treated with thyrotropin-releasing
hormone showed significant improvement in Neural Scores 14 days post-injury, but there
were no significant differences in morphometric parameters between saline-and TRH-
treated rats [19]. TRH has disadvantages, including its analeptic, endocrine, and auto‐
nomic effects, but a new generation of TRH analogs has been developed that have the
protective effects of TRH without its adverse effects [20].
6. Repair and regeneration
A variety of promising substances have been tested in animal models, but few have had
potential  application to  human spinal  cord injury  (SCI)  patients.  This  category of  treat‐
ment includes both the pharmacological intervention using FDA approved drugs and cell
transplantation.  (The latter  will  be discussed in detail  in  the forthcoming titles).  Several
drugs  were  tested  for  their  efficacy  in  restoring  spinal  cord  function  as  evidenced  by
multiple preclinical studies. Some of the Drugs such as Cethrin [47-50], rolipram [41-45],
ATI-355  [45-51],  chondroitinase  [51-56]  and  riluzole  [57-64]  were  thoroughly  reviewed
which  are  not  limited  to  neuroprotection,  axonal  regeneration,  motor  neuron  recovery,
reduction in muscle spasms, enhanced sprouting of corticospinal axons, improved behavio‐
ral  outcome  and  corticospinal  plasticity,  recovery  of  forelimb  function,  inhibition  of
apoptosis and suppression of glial scar formation with varying degree of success. The major
drawback of the pharmacological intervention is their side effects and direct application in
human trials.
6.1. Plasticity enhancement and rehabilitation
An inability to perform self-care activities is considered a “burden of care” by the medical
community. The individual with acute SCI faces many challenges with the resumption of self-
care tasks. Hence considerable efforts have been taken by the therapist in order to guide the
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patient move their upper limb and lower limb and support their body weight after a spinal
trauma. Upon discharge from a hospital setting, family members, other caregivers, or both
share the burden of care. Medical insurance programs have required reliable data on which to
determine benefits, including coverage of durable medical equipment, treatment, and care
giving assistance. Task specific training i.e., activities of daily living (ADL) which include self
feeding, bathing, bowel and bladder maintenance, dressing, hygiene maintenance, computer
usage etc., plays a central role for the patient to be independent. Other techniques such as body
weight support and treadmill training using upper and lower limb orthosis and knee orthosis,
have shown recovery in maintaining the body gait and postures. Tilt table standing, robot-
aided gait training, electric stimulated wheel chairs are also used in recent days for posture
maintenance. Recreation and leisure skill development such as reading, writing, painting,
exercises, All-Terrain Vehicles (ATVs) (cycling, fishing, horseback riding, climbing, diving,
etc) arm ergometry and Nautilus-type machines. Although these techniques are considered to
be promising, less is known about their mechanism and efficacy on the functional recovery.
Hence a deeper understanding of the underlying mechanism for adaptation and plasticity after
spinal cord injury is needed to improve rehabilitation regimes [65-81].
6.2. Non pharmacological intervention for the treatment of SCI
Functional electrical stimulation (FES) is the technique of applying safe levels of electric current
to activate the damaged or disabled nervous system. Although no absolute contraindications
exist for the use of externally applied FES, a patient with a cardiac demand pacemaker or an
automatic implanted defibrillator should be approached with extreme caution. Some of the
relative contraindications for FES include patients with cardiac arrhythmias, congestive heart
failure, pregnancy, electrode sensitivity, and patients with healing wound(s) that could be
stressed during stimulation (i.e., muscle stimulation would adversely move healing tissues).
As with any implant in the body, individuals with implanted FES systems need to obtain
antibiotic prophylaxis when undergoing invasive procedures such as oral surgery. Functional
uses for FES after SCI include applications in standing, walking, hand grasp (and release),
bladder, bowel, and sexual function, respiratory assist, and electro ejaculation for fertility.
[82-88]. Functional magnetic stimulation (FMS) can be defined as a technology that applies a
time varying magnetic field to produce useful bodily function. There were no significant side
effects of magnetic stimulation that were reported. However safety consideration such as
magnetic effect, electric effect and power dissipation should be kept in mind during stimula‐
tion. A few reports have shown that repetitive transcranial magnetic stimulation may result
in increased seizure activities [89-94].
Hypothermia, CSF Drainage, durotomy and subarachnoid perfusion, Functional electrical
stimulation, Electromagnetic stimulation, hyperbaric oxygen were tried with some success.
But none of them reached to the level of functional therapeutic options.
6.3. Replace or assist function
Over the past 2 decades, advances in understanding the pathophysiology of spinal cord injury
(SCI) have stimulated the recent emergence of therapeutic strategies. Functional repair of the
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injured central nervous system (CNS) is one of the greatest challenges addressed by neurobi‐
ologists. The rapidly growing field of stem cell biology offers a promising future for cell
replacement and neural regeneration therapies. Stem cells have seen its good days with success
in Parkinson disease and Huntington’s disease and hold a long history of research on the
possible use of progenitor cells in the treatment of SCI. The application of cell-based therapies
to SCI is a natural expansion of research in other fields, such as cancer, diabetes, and heart
diseases.
Spinal Cord Injury and Stem cells: Some Cellular transplantation strategies
Spinal cord injury though uncommon leads to profound lifelong disability and systemic
effects. So far no single therapy have proved its efficacy,.therefore combination therapies might
hold the future design. In order to repair the injured spinal cord, it is essential to reduce
secondary damage and promote regeneration. Several biological agents such as proteins,
antibodies, enzymes and cells were used to achieve this goal..
The adult spinal cord has an endogenous progenitor cell pool said to have been located, in the
ependymal region around the central canal. [95-97]. While others believe their presence
throughout the spinal cord [98]. The response of these endogenous cells post injury is insuffi‐
cient and does not bring about adequate recovery following SCI [95-97]; probably due to the
insufficient cell numbers, microenvironment at the injury site, and presence of tissue debris.
Neural inflammation, immune mediated destruction and loss of vascularity also becomes
major hindrance. There could be an imbalance between the degree of repair vs damage. Cell
transplant strategies have the potential of reducing such secondary damage and promoting
regeneration by replacement of dead cells and production of Neurotrophic factors promoting
regeneration [99-101].
Oligodendrocytes and astrocytes are the major supportive cells within the central nervous
system and are responsible for myelination of axons, so it is believed that replacement of this
cell population will support the frame work in regenerative processes.
Immature glial cells have been shown to reduce the inhibitory properties of the lesion epicentre
and promote axonal growth [102]. Immature oligodendrocytes provide remyelination after
injury [103], whereas immature astrocytes promote axonal growth and survival after injury
[104]. A recent study supports the idea of ensuring both of these cell types, astroglial, are
replaced, since oligodendrocytes precursors failed to remyelinate the spinal cord in the absence
of astrocytes.
Cao et al., [99] has demonstrated that after the transplantation of stem cells into lesioned adult
rat spinal cord most of these transplanted cells have differentiated into astrocytes and no
neurons or oligodendrocytes were observed. This indicates that it would be essential to
transplant a progenitor cell population capable of trans-differentiating into a mixed lineage in
vivo or should be able to secrete neurotrophic factors in vivo. Studies have elucidated that MSCs
do have the capacity to Trans-differentiate into the astroglial lineage and also secrete cytokines
which may be essential for regeneration in spinal cord injury.
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6.4. Proposed scope of using stem cells / regenerative medicine
Type of stem cells Species Injury type Site ofinjection Results Salient features Reference
BM MSC
Transgenically
labeled BMMSC
(autologous) and
lineage restricted
neural precursor
(LRNP)
(2x106 cells)
Inbred
Fisher-344
rats
Partial cervical
hemisection
injury
Intravenously,
Intraventricula
rly,
Intrathecally
and Lumbar
puncture
Intravenous route –
least efficient.
Intrathecally and
intraventricular
administration
shows enhanced
cell migration and
grafting
Axonal growth
was observed
around the
transplanted
cells.
Grafted LRNP
cells
differentiation
into mature
neurons, their
survival and
integration
within the host
spinal
Cord might lead
to functional
recovery.
Ajay bakshi
et al
BMSCs and GCSF Male Wistarrats
Compression
lesion
Intravenously
(BMSCs) and
subcutaneousl
y (GCSF)
Higher BBB scores
and better recovery
of hind limb
sensitivity
Significant
increases in
the spared
volume of white
matter due to
the synchronized
action of various
factors released
by MSCs
Lucia
Urdzíková et
al
Bone-marrow-
derived
mesenchymal stem
cell (autologous
and allogenic)
Adult Beagle
dogs Intrathecal
Improved
neurological signs
in pelvic limbs
Significant high
Olby scores
Recovery may be
due to the
synchronized
action of various
factors as
evidenced by
high rate of
mRNA expression
for neurotrophic
factors.
Dong-In
Jung et al
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Type of stem cells Species Injury type Site ofinjection Results Salient features Reference
LA MSC
Adipose-derived
stem cells
(allogenic)
Adult
mixed-breed
dogs
Epidural
balloon
compression
Injured site
Nerve conduction
velocity was
significantly
improved
GFAP, Tuj-1 and
NF160 were
observed
Neuronal
transdifferentiati
on
Survived MSCs
produces large
amounts of bFGF
and VEGFR 3
which aid the
recovery
Cotransplantation
of Mouse Neural
Stem Cells (mNSCs)
With Adipose
Tissue-Derived
Mesenchymal Stem
Cells
Adult Male
Sprague-
Dawley rats
Clip
compression
Epicenter of
the injured
spinal cord
AT-MSCs inhibited
the apoptosis of
mNSCs
mNSCs
transplanted
with AT-MSCs
showed better
survival rates
Biomolecular
substances
secreted by
ATMSCs improve
mNSC survival
and inhibit mNSC
apoptosis, mainly
VEGF
Jin Soo Oh
et al
WJ MSC
Human Umbilical
Cord-Derived
Schwann-Like Cell
Combined with
Neurotrophin-3
Adult
Female SD
rats
Transection Lesion site
NT-3
administration
significantly
promoted the
survival
of the grafted cells
Improved motor
function and
promotes neurite
outgrowth
GDNF, BDNF,
NT-3 and
bFGF provided
neurotrophic
support
Guo Yan-
Wu et al
Human umbilical
cord mesenchymal
stem cells
Female
Sprague-
Dawley rats
Weight drop
method
(contusion)
At the dorsal
spinal cord 2
mm rostrally
and 2 mm
caudally to the
injury site
Significant
Recovery of
hindlimb
locomotor function
Increased length of
neurofilament-
positive fibers and
increased numbers
of growth cone-like
structures
Transplanted
cells survived,
migrated over
short distances,
and produced
large amounts of
glial cell line-
derived
neurotrophic
Hu SL et al
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Type of stem cells Species Injury type Site ofinjection Results Salient features Reference
Fewer reactive
astrocytes were
observed
factor and
neurotrophin-3.
Human umbilical
cord mesenchymal
stem cells
Adult
Female
Sprague-
Dawley rats
Transection Lesion site
Promotion of
regrowth of injured
corticospinal fibers
change in the
distribution of
astrocytes in spinal
cords
reduction in the
activation of
microglia
Production of
large amounts of
human
neutrophil-
activating
protein-2, NT-3,
bFGF,
glucocorticoid
induced TNF-
receptor, and
VEGFR 3 in host
spinal cord, may
have helped in
spinal cord
repair.
Chang-
Ching Yang
et al
GLIAL CELLS
Multineurotrophin-
Expressing Glial-
Restricted
Precursor Cells
Adult
Female
Fischer 344
rats
Contusion Lesion site
Improved
transcranial
magnetic motor-
evoked potential
responses
Improved
Electrophysiologica
l and locomotor
functional recovery
Grafted GRPs
formed normal-
appearing myelin
sheaths around
the axons in the
ventrolateral
funiculus (VLF) of
spinal cord and
restores the
conduction.
Qilin Cao et
al
NSC/ NSPC
poly(lactide-co-
glycolide) (PLGA)
polymer seeded
with human neural
stem cells
African
green
monkey
Hemisection Lesion site
Enhanced hindlimb
motor neuron
performance
Major
mechanism of
action of
implanted cells
may be due to
trophic support
rather than
Pritchard et
al
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Type of stem cells Species Injury type Site ofinjection Results Salient features Reference
neuronal
replacement
Spinal cord-derived
NSPCs and BMSCs
Adult male
rat
Clip
compression Lesion site
No functional
improvement was
seen in either
transplant group.
But significant
inverse corelation
between the
functional scores
and the number of
transplanted
astrocytes was
observed
Differentiation of
NSPCs into
astrocytes and
oligodendrocytes
promoting
remyelination,
and potential
axonal guidance
Parr et al
Neural stem cells Marmoset Contusion Lesion site
Recovery of motor
function
was observed
mainly in the
hindlimbs
Significantly higher
spontaneous
movement
Grafted human
NSCs survived
and
differentiated
into neurons
astrocytes and
oligodendrocytes
and
restores motor
function
Iwanami et
al
Epidermal Neural
Crest Stem Cell
(EPI-NCSC)
Wild type
C57BL6/J
and
C57BL/6-
TgN
(ACTbEGFP)
1Osb
Contusion Intraspinal
Differentiated into
gabaergic neurons
and myelinating
oligodendrocytes
combination of
pertinent
functions
including cell
replacement,
neuroprotection,
angiogenesis and
modulation of
scar
formation
Sieber
Spinal cord-derived
neural stem/
progenitor cells
(NSPCS) and Bone
Marrow-derived
Rat Compression Lumbarpuncture
Expression of
oligodendrocyte
markers
wide
dissemination of
cells in the
subarachnoid
Mothe et al
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Type of stem cells Species Injury type Site ofinjection Results Salient features Reference
mesenchymal
stromal cells
(BMSCS)
space of the
spinal cord
Immortalized
human NSC line
over expressing
VEGF (F3.VEGF
cells)
Adult
Sprague–
Dawley
female rats
Contusion
2 mm rostral
and 2 mm
caudal from
the lesion
epicenter
Elevated the
amount of VEGF in
the injured spinal
cord tissue and
increased
phosphorylation of
VEGFR flk-1
Enhanced cellular
proliferation and
tissue sparing
VEGF increased
the number of
early
proliferating cells
that
differentiated
into mature
oligodendrocytes
Kim et al
Poly(lactic-co-
glycolic acid)
(PLGA) seeded
with neural stem
cell (NSC)
Adult dog Hemisection Lesion site
Grafted NSC
survived the
implantation
procedure and
showed migratory
behavior
Ectopic
expression of a
therapeutic
neurotrophin-3
gene was
observed
Kim et al
hESC derived PROGENITOR CELLS
hESC-derived
oligodendrocyte
progenitors (OPC)
and/or
motoneuron
progenitors (MP)
Adult rats Completetransection Site of injury
Locomotor
function was
significantly
enhanced
OPC and MP
survived, migrated,
and differentiated
into mature
oligodendrocytes
and neurons
The recoveries
can be attributed
to the
reconnection of
the axons above
and below the
lesion site
SLAVEN
ERCEG et al (
hESC derived
Oligodendrocyte
Progenitor Cells
Female
Sprague
Dawley
adult rats
Contusion Lesion site
Transplanted cells
survived,
redistributed over
short distances,
and differentiated
into
oligodendrocytes
Widespread
oligodendrocyte
remyelination
throughout
the white matter
Keirstead et
al
Table 2. Provides a list of preclinical animal studies conducted for spinal cord injury
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6.4.1. Current status of cell replacement therapy
During the last 2 decades, the search for new therapies has been revolutionized by the
discovery of stem cells, which has inspired scientists and clinicians to search for stem cell–
based reparative approaches to many diseases. The adult spinal cord harbors endogenous
stem/progenitor cells, collectively referred to as neural progenitor cells (NPCs) that might be
responsible for normal turnover of the cells. However, the proliferative activity of endogenous
NPCs is too limited to support significant self-repair after SCI. Thus, various cellular trans‐
plantation strategies have been adopted in models of SCI.
Current goals of cell replacement approach are broadly classified into two broad types: 1)
regeneration and 2) repair. Alternatively the cell transplanted may promote protection to the
endogenous cells from further damage.
A summary of cell therapy approaches has been listed in Table 2 mentioned above.
6.4.2. Different cell types proposed to have therapeutic potential
Human Embryonic Stem Cell derived progenitor cells
Cocultures of hESC derived ologodendrocytes with or without motor neuron progenitors have
been used for the treatment of SCI by different researchers with different injury models [14,
17]. The functional recovery concluded by both study is in vivo differentiation of the trans‐
planted cells into oligodendrocytes and neurons promoting remyelination and axonal re-
growth.
Adult derived stem cells
Bone marrow derived stem cells
In a hemisection model of rats, Bakshi et al has shown that BMSC co-transplanted with that of
neural progenitors shows better cell migration and grafting when injected intraventricularly
or intrathecally. However, intravenous route shows the least cell migration to the site of injury.
Alternatively, Urdzíková and his team reported that when BMSCs were transplanted intra‐
venously with GCSF in subcutaneous region, spared white matter increases in size and
enhanced recovery of hind limb sensitivity was observed. A canine model of injury using both
auto and allogeneic BMSCs transplanted intrathecally shows improvement in neurological
signs. But the mechanism of recovery observed was the synchronized action of the growth
factors released by the grafted cells [11].
Strangely no functional recovery was observed in rat model of SCI wherein a co culture of
Spinal cord-derived NSPCs and BMSCs were transplanted at the lesion site. Alternatively a
reverse correlation was observed between the functional scores and number of astrocytes
transplanted [25]. But the same group of cells when injected via LP shows potent oligoden‐
drocyte marker [21].
Adipose tissue derived stem cells
In 2009, Hak-Hyun Ryu and his colleagues reported the use of adipose derived stem cells on
a canine model of SCI using compression method. ADMSCs show better recovery by signifi‐
Topics in Paraplegia244
cant increase in nerve conduction, neuronal transdifferentiation and production of bFGF and
VEGFR3 in large quantity. In yet another study [2] using rat as animal model of SCI, trans‐
planted ADMSC and Mouse Neural Stem Cells (mNSCs) and observed that ADMSC protect
mNSCs from apoptosis and increases the survival rates by secreting biomolecular substances,
preferably VEGF in various conditions like hypoxia, oxidative stress and combined injury.
Human umbilical cord mesenchymal stem cells
In two trans-section and one contusion injury model of rats studied using Human umbili‐
cal cord mesenchymal stem cells had revealed that the grafted cells survived, migrated and
produced large amount of GDNF, BDNF, NT-3, bFGF [9] glial cell line-derived neurotro‐
phic factor, [13] neutrophil-activating protein-2, glucocorticoid induced TNF-receptor, and
VEGFR 3 [16].
Glial precursor cells
Improved transcranial magnetic motor-evoked potential responses and improved electrophy‐
siological and locomotor functional recovery was observed in rat contusion model of spinal
trauma using Multi-neurotrophin-expressing glial-restricted precursor cells. The reason
behind the functional recovery in restoring conduction was proposed to be formation of myelin
sheath around the axons by the grafted cells [12].
Neural stem cells and Neural progenitor cells
Various animal injury models were studied for the transplantation of NSC/NPC. This include
primates and rodents model. NSC in PLGA scaffold was tested in African Green Monkey using
hemisection and Pritchard concluded the regulatory mechanism as the signaling by various
factors released by NSCs [10]. In a contusion model of injury using marmoset, Iwanami et al
[18] reported the differentiation of NSPCs into astrocytes and oligodendrocytes which
promotes remyelination and promotes functional recovery. In another contusion injury model,
the efficacy of EPI-NSC in restoring function was due to differentiation of grafted cells into
Gaba-ergic neurons and myelinating oligodendrocytes resulting in neuroprotection, angio‐
genesis and scar modulation [18].
Expression of a therapeutic neurotrophin-3 gene, which leads to the recovery, was observed
when PLGA coated with NSC was grafted in a canine hemisection model [20]. While others
[25] observed no functional improvements in either groups transplanted with spinal cord-
derived NSPCs and BMSCs on rats at the lesion site, Mothe et al observed recovery by injecting
the cells via LP. Differentiation of SC derived NSPC into astrocytes and oligodendrocytes were
observed by both the teams. Elevated amount of VEGF in the injured spinal cord tissue and
increased phosphorylation of VEGFR flk-1 enhanced cellular proliferation and tissue sparing
and increase in the density of blood vessels was the result reported by Kim et al using
immortalized human NSC line over expressing VEGF (F3.VEGF cells) in a contusion model of
injury in rats [15].
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6.5. Clinical trials for SCI
Cell transplantation therapies have become a major focus in pre-clinical research as a prom‐
ising strategy for the treatment of spinal cord injury. Various types of stem cells such as bone
marrow stromal cells (BMSCs), adipose tissue Mesenchymal stem cells (ADMSCs), Schwann
cells, olfactory ensheathing cells (OECs), neural stem cells or progenitor cells have been
reported for their potential to form myelin, promote axonal regrowth and guidance, bridging
the site of injury.
More than a dozen of clinical trials have been registered in the official website of clinical trials
(http://www.clinicaltrials.gov). A brief listing of the selected trials is given below.
The results obtained are as follows:
S. No NCT studynumber Title/ Brief summary
Study type/
phase Study status
1 NCT01325103
To evaluate autologous bone marrow stem cells
transplantation as a safe and potentially beneficial
treatment for patients with spinal cord injury
Interventional,
Phase I
Active, not
recruiting
2 NCT01490242
Phase I/II, multicenter, prospective, non-randomized,
open label study to evaluate the safety/efficacy of
autologous bone marrow-derived stem cell
transplantation in spinal cord injury patients.
Interventional,
Phase I / II Recruiting
3 NCT01393977
To study the efficacy difference between Rehabilitation
Therapy and Umbilical Cord Derived Mesenchymal
Stem Cells transplantation
Interventional,
Phase II Recruiting
4 NCT01328860
1. To see if Bone Marrow Cell harvest and
transplantation are safe in children and
2. To determine if late functional outcome is improved
following Bone Marrow Cell transplantation.
Interventional,
Phase I Recruiting
5 NCT01446640
A phase I/II trial designed to establish the safety and
efficacy of intravenous combined with intrathecal
administration of autologous bone marrow derived
mesenchymal stem cells
Interventional,
Phase I / II Recruiting
6 NCT01162915
A Phase I, single-center trial to assess the safety and
tolerability of an intrathecal infusion (lumbar puncture)
of autologous, ex vivo expanded bone marrow-derived
mesenchymal stem cells
Interventional,
Phase I
Active, not
recruiting
7 NCT01321333
A Phase I/II Study of the Safety and Preliminary Efficacy
of Intramedullary Spinal Cord Transplantation of
Human Central Nervous System (CNS) Stem Cells
Interventional,
Phase I / II Recruiting
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S. No NCT studynumber Title/ Brief summary
Study type/
phase Study status
(HuCNS-SC®) in Subjects With Thoracic (T2-T11) Spinal
Cord Trauma
8 NCT01186679
Surgical Transplantation of Autologous Bone Marrow
Stem Cells With Glial Scar Resection for Patients of
Chronic Spinal Cord Injury and Intra-thecal Injection for
Acute and Subacute Injury
Interventional,
Phase I / II Completed
9 NCT01274975
To assess the safety of intravenous autologous adipose
derived mesenchymal stem cells transplant in spinal
cord injury patients.
Interventional,
Phase I Completed
10 NCT00816803
To assess the safety of autologous bone marrow
derived cell transplant in chronic spinal cord injury
patients.
Interventional,
Phase I / II Completed
11 NCT01217008
To evaluate the safety of GRNOPC1 administered at a
single time-point between 7 and 14 days post spinal
cord injury
Interventional,
Phase I
Active, not
recruiting
12 NCT01231893
Assessment of the safety and feasibility of
transplantation of autologous olfactory ensheathing
glia and olfactory fibroblasts obtained from the
olfactory mucosa in patients with complete spinal cord
injury.
Interventional,
Phase I Recruiting
In an article published, Wolfram Tetzlaff et al has reviewed in detail, all the types of cells
being used in the treatment of spinal cord injury from the available pre-clinical literature.
Their  review shows that  rodent  stem cells  have  been most  extensively  studied for  SCI.
Limited  studies  have  been  done  on  human stem cells.  Majority  of  trials  are  with  bone
marrow stromal  cells.  Also reported was,  while  chronic  treatments  were rare  and often
failed to yield functional benefits, all the preclinical studies conducted, was in acute and
subacute stage [8].
Also  Fehlings  et  al  [9]  in  his  recently  reviewed  article  has  shown  the  efficacies  and
limitations of every type of cells, either alone or in various combinations as registered for
trial studies, in use and has demonstrated the potential use of other promising candidate
stem cells evaluated in pre-clinical studies but are not yet in Clinical Trials. Also they have
made recommendations for the conduct and evaluation of pre-clinical studies and clinical
trials of cell therapies for SCI [9].
However no clinical intervention is risk free and we require understanding more on the
pathophysiology of SCI and the clinical potential of stem cells to translate the use of the same
as a therapeutic agent.
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NPCs/OPCs:
Geron conducted a Phase 1 clinical trial in the United States in October 2010, to evaluate the
safety of human embryonic stem cell-based product candidate, GRNOPC1, in patients with
thoracic spinal cord injuries. Accordingly, GRNOPC1, an investigational product for treatment
of Spinal Cord Injury, is a population of living cells containing oligodendrocyte progenitor
cells (OPC).
HUMSCs:
WJCs can undergo repeated freeze–thaw cycles without a significant loss of viability, meso‐
dermal differentiation potential, and without accumulating karyotypic abnormalities and thus
represent a potential for the treatment of the neurodegenerative disorders including SCI. Two
studies so far have examined the use of WJCs in SCI models, but were poorly conceived and
designed.
6.6. Ongoing clinical trials for spinal cord injury using stem cells
Based on the encouraging preclinical animal results, Sarel et al, has conducted a phase II clinical
trial of a cell therapy for patients with acute spinal cord injury using monocytes isolated from
peripheral blood of human donors. They were able to stimulate by co-incubation with skin
tissue, producing a distinct cellular phenotype which is said to be associated with wound
healing. These features of skin-co incubated macrophages suggest possible mechanisms by
which they may support an immune response that promotes neuronal cell survival and repair.
Jones et al., 2004 [105] observed the long-term outcomes after complete spinal cord injury
followed by subsequent treatment with a therapy consisting of autologous incubated macro‐
phages that have been pre-incubated with autologous skin and injected into the lesion site.
The study so far has been conducted on 14 patients. Recovery of clinically significant neuro‐
logical function has been observed in several subjects after treatment, whereas untreated
patients with complete SCI rarely recover significant function.
Auerbach et al., 2004 [106], has conducted open-label, non-randomized trials to assess the safety
of autologous macrophages in 16 patients with acute complete spinal cord injury. The
macrophages were prepared from monocytes isolated from patient blood and co-incubated
with autologous skin tissue. The cells were then injected into the spinal cord parenchyma
within 14 days of injury. The study shows that administration of autologous macrophages has
a favorable benefit to risk ratio for the treatment of patients with acute, complete spinal cord
injury.
Keirstead et al., 2005 [107] have shown human embryonic stem cells differentiate into oligo‐
dendrocytes in high purity and showed regeneration of the spinal cord in rat. On the basis of
this study Geron Inc is currently conducting a FDA approved phase-I clinical trial.
Moviglia et al., 2006, [108] demonstrated a case report of two patients who were administered
BM-MSCs co cultured with an autologous pure population of T cells, intravenously 48 hours
prior to transplantation of trans-differentiated NCS. This was followed up with 6 months of
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neuro-rehabilitation. The authors conclude that in vitro cultures of MSCs and anti CNS T cells
can induce transdifferentiation of MSCs into neural stem cells.
Kang et al., 2005 [109] transplanted human umbilical cord cells into a 37 year old female with
T11/T12 complete injury and have observed recovery but have not ruled out the fact that the
laminectomy itself may have released compressed areas of the spinal cord and brought about
recovery.
Zhou et al., 2004 differentiated BM-MSCs into neural stem cells and transplanted them into
SCI patients. 3 patients reported adverse events of intracranial infection requirement treat‐
ment. This study has not mentioned the baseline status of the patients, neither the details of
the follow-up study conducted nor the details of the intervention.
Deda et al., 2009 [110], reported that autologous hematopoietic progenitor stem cells are an
effective and safe method for treatment of chronic SCI. In this study autologous hematopoietic
progenitor stem cells were injected at the site of injury and three weeks post transplantation
the patients have demonstrated improved sensory and motor functions.
7. Our experience
Realizing the unmet medical need in producing reasonable clinical recovery in spinal cord
injury we have designed a preclinical experimental animal study. We developed a rodent
model of spinal cord contusion injury and transplanted bone marrow derieved mesenchymal
stem cells both at the site of injury and into the CSF using lumbar puncture technique. The
results were very encouraging [111]. Motivated by this an initial pilot study was conducted
on 10 patients with chronic spinal cord injury. The initial results showed only partial sensory
improvement. Only 2 patients showed minimal motor improvement but not clinically useful.
Surprisingly 4 of them showed reasonable improvement in bladder function. This fact has
triggered further interest in us to pursue this and try different methods to improvise the clinical
results. Though an attempt was made to quantify the recovery, none of the existing methods
were satisfactory.
But this study has raised several questions like a)Timing of intervention) Route of cell
administration c)Dosage of cells D)Type of cell e) Number and interval of doses f)Autologous
vs allogenic MSC g) problems of chronic injury h)Method of monitoring, evaluation and
quantifying the results.
In our further study we attempted to address some of these questions: 1) route-Intrathecal,
direct at the site of injury, Direct delivery into the cord during surgery 2) excision of scar 3)
scaffold to bridge the damaged ends of the cord 4) number of injections 5) number of cells 6)
Cell type – mesenchymal autologous, allogenic & mononuclear 7) source-bone marrow,adi‐
pose and Wharton jelly 8) additional systemic injections. 100 volunteers with clinically
complete cord injury were recruited. Clinical, MRI and tractography were done at baseline
and at periodic intervals to monitor the course of events post stem cell infusion.
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8. Study plan
The objective of this study was to demonstrate the safety and feasibility of various stem cells
as a possible therapeutic strategy for Spinal cord injury. For this, 52 volunteers were recruited
and grouped into 4, on the basis of stem cells they received for the treatment. Group 1 received
autologous bone marrow derived mononuclear cells (BMMNCs) for transplantation, group 2
were infused with autologous bone marrow derived Mesenchymal stem cells (BMMSCs),
while group 3 were transplanted with different allogeneic stem cells (subgroup 1: Bone
Marrow derived Mesenchymal cells, subgroup 2: Wharton’s Jelly derived Mesenchymal stem
cells (WJMSCs) and subgroup 3: Adipose Tissue derived Mesenchymal cells (ADMSCs). Also,
in this study, we demonstrated, delivery of stem cells via 3 different routes (laminectomy,
lumbar puncture, site of injury guided by CT scan and intravenous delivery) were safe and
feasible and do not cause any infections and adverse reactions post transplantation.
a. Regulatory approval, Informed consent:
As per national guidelines, approval from institutional ethics committee (IEC) was taken and
informed consent was obtained from every patient who participated in the study. Any
deviations, drop-outs and adverse events were documented and the IEC informed.
b. Patient selection:
Patients were enrolled for this study as per the inclusion and exclusion criteria designed by
and adapted in a pilot clinical study [1]. The inclusion Criteria in the study was as follows
i. the patients could be of either sex,
ii. must be between the ages 18 and 55 years,
iii. the level of spinal injury between C4 and T10 level (neurologic),
iv. (SCI was clinically complete and categorized as per the American Spinal Injury
Association (ASIA) impairment scale.
Exclusion criteria for the study was
i. Difficulty in assessing the size and location of the injury multiple sites of injury,
ii. gun shot or penetrating injuries,
iii. serious pre-existing medical conditions, disease or impairment that precluded
adequate neurologic examination
iv. Respiratory insufficiency requiring support.
v. if he/she is enrolled in any other clinical trial
vi. Not able to understand and comply with follow up
vii. Diagnosed with infections like HIV, HCV,CMV and VDRL.
viii. Fixed deformities.
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c. Screening of the patients:
Before enrollment each patient was screened for HIV: Human Immunodeficiency Virus; HBV:
Hepatitis B Virus; HCV: Hepatitis C Virus; CMV: Cytomegalovirus; and VDRL: Venereal
Disease Research Laboratory, by a nationally certified testing laboratory.
d. Isolation and propagation of stem cells:
i. Autologous Bone Marrow derived Mesenchymal Stem Cells:
Patients willing to undergo autologous cell transplantation were screened 7 days before the
aspiration for infectious disease mentioned above. Thereafter, BM-derived MSC were isolated
and expanded using a method reported previously [1].
Briefly, 60 ml BM was aspirated aseptically from the iliac crest of each patient under aseptic
conditions. The BM was diluted (1:1) with Knockout Dulbecco’s modified Eagle’s medium
(KO-DMEM) and centrifuged at 1800 r.p.m. for 10 min to remove anticoagulants. The super‐
natant was discarded and the BM washed once with culture medium. Mononuclear cells
(MNC) were isolated by layering onto a lymphoprep (Axis Shield, Norway) density gradient.
The MNC present in the buffy coat were washed again with culture medium. The mononuclear
fractions containing MSC were plated at a density of 1000 cells/cm2 onto T-75cm2 flasks and
cultured in KO-DMEM. The media were supplemented with 10% fetal bovine serum (FBS),
200 mM Glutamax and Pen-Strep. The cultures were maintained at 370C in a humidified 5%
CO2 atmosphere for 2 days. The non-adherent cells were removed after 48 h of culture and
replenished with fresh medium. Subsequently, the medium was replenished every 5th day
until the required number of cells obtained. Once confluent, the culture flasks were washed
with Dulbecco`s Phosphate Buffered Saline (DPBS) and harvested using 0.25% Trypsin-EDTA
solution and re-plated in 5 cell stacks (Corning, USA) for further expansion till the required
number of cells obtained. On the day of transplantation the cells were harvested and sus‐
pended in saline solution, packed in sterile container and given for the transplantation
procedure.
ii. Autologous Bone Marrow derived Mononuclear cells (MNCs):
All the patients were examined by a designated medically qualified staff member to establish
their eligibility for bone marrow aspiration. Briefly, 60 ml BM was aspirated aseptically from
the iliac crest of each patient under aseptic conditions. The BM was diluted (1:1) with Knockout
Dulbecco’s modified Eagle’s medium (KO-DMEM) and centrifuged at 1800 r.p.m. for 10 min
to remove anticoagulants. The supernatant was discarded and the BM washed once with
culture medium. Mononuclear cells (MNC) were isolated by layering the bone marrow
samples onto a lymphoprep (Axis Shield, Norway) density gradient. The MNC present in the
buffy coat were washed again with culture medium and then with saline for 2-3 times,
resuspended in the same and given for infusion.
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9. Scaffolds
Scaffolds are basically structures to support and connect the cut ends of spinal cord. They are
used after scar excision or otherwise in chronic injuries to bridge the healthy ends. The stem
cells are deposited over the membrane. It helps to hold the cells in place, and grows along
using this as support.We have used Gelfoam as well as a special biological membrane, which
is inert and biocompatible made out of Chitosin. It is a thin and transparent glucosamine
polymer. Stem cells have grown in sheets over this membrane in our invitro studies.
In acute phase, the chemical changes resulted out of injury presumably attracts stem cells even
after remote injection whereas in chronic injuries there are additional problems.
1. Scar intervenes ends of normal cords 2.In severe injuries there is thinning and atrophy
causing anatomical discontinuity. 3. Due to ongoing degeneration there is a functional void
between the two ends, with or without an abnormal cord intervening. The main purpose of
scaffolds is to bridge this gap and create continuity for the cells to reach both ends.
10. Screening of potential donors for bone marrow aspiration
Potential voluntary donors were interviewed, counseled and examined by the investigator or
a designated medically qualified staff member to establish their eligibility for bone marrow
aspiration. Donors were informed with full description about the nature and purpose of the
aspiration and written consent were obtained from them before proceeding with study. Some
of the inclusion criteria include (i) the donor must be healthy (ii) may be of either sex (iii) must
be between 18-30 years of age (iv) able to understand the voluntary donation program, and
ready to provide voluntary written informed consent. The donors were excluded if (i)
diagnosed with a past history of illness such as autoimmune disorders, tuberculosis, malaria
and any other infection, any illness which precludes the use of general anesthesia, history of
malignancy, diabetes, hypertension, significant heart disease, genetic or chromosomal
disorders, history of any inherited disorders, hemoglobin less than 10, and pregnant women.
Also, at the time of obtaining informed consent they were screened for infection with human
immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), cytomegalovirus (CMV),
and syphilis (VDRL) and excluded, if found positive.
11. Allogeneic BM-MSCs
As per the donor selection criteria, donors were recruited and bone marrow samples were
aspirated from the iliac crest of the donors and further processed for the isolation of mono‐
nuclear fraction using Lymphoprep (Axis Shield, Norway) density gradient. Thus obtained
fraction was seeded in T-75cm2 and cultured at 37°C in 5% CO2 atmosphere. The non-adherent
cells were removed after 48 hours by replacing the medium and the adherent cells were grown
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for additional 4 or 5 days till it reached 80-85% confluency. On confluency, confluence,
adherent cells were detached by treatment with a Trypsin-EDTA solution and re-plated at a
density of 1000 cells/cm2 in 5 cell stacks and cultured in the same condition for 14-16. The cell
stacks were checked regularly and replenished with medium on every 5th day. The cells were
then harvested at 80-90% confluency and cryopreserved in 10% Dimethyl Sulfoxide (DMSO,
Sigma-Aldrich) and 85% Plasmalyte (Baxter, USA) and 5% Human Serum Albumin (HSA,
Baxter) in liquid nitrogen till further use.
12. Adipose tissue derived mesenchymal stem cells
The use of lipoaspirate as a source for stem cells with multipotent differentiation poten‐
tial offers a far less invasive procedure for cell sampling than the aspiration of bone marrow
(BM), and numbers of stem cells obtained are reportedly higher in lipoaspirate than its BM
counterpart. Lipoaspirate, an otherwise disposable byproduct of cosmetic surgery, has been
shown to contain a putative population of stem cells,  termed adipose-derived stem cells
(ADSCs) that share many similarities to marrow stromal cells (MSCs) from BM, including
multilineage  differentiation  capacity.  Furthermore,  these  cells  also  show  high  colony-
forming unit frequencies as well as an apparent pluripotent ability to differentiate to cells
of a neuronal phenotype [9, 10].
This protocol describes the preparation of MSCs from human lipoaspirate obtained from
cosmetic surgery. Briefly, the liposuctioned fat first washed thoroughly in phosphate-buffered
saline (PBS) with antibiotic solution (Penstrep, 2X), until the bottom layer containing blood
cells contaminant was clear, before being subjected to enzymatic digestion using collagenase
type I (0.2%, diluted in KO-DMEM) for 45-60 minutes at 37°C in shaking condition, in order
to obtain a soupy single-cell suspension. After digestion, the action of collagenase was
neutralized by the addition of FBS. The suspension was then mixed well and passed through
40 μm cell strainer before being subjected to centrifugation at 1400 rpm for 10 minutes. After
centrifugation, cell pellet, termed as stromal vascular fraction (SVF) is resuspended in KO-
DMEM and seeded in a T-75cm2 flask at a density of 1,000 cells/cm2. The non-adherent cells
were removed after 48 h of culture and replenished with fresh medium. Subsequently, the
medium was replenished every 4th day and the cells were harvested at 80% confluency and
replated in 5 cell stacks to obtain the sufficient number of cells required for the infusion. The
plates were checked for confluence every day and the cells are fed with fresh medium. After
the cell stacks were confluent enough, the cells were harvested using Trypsin-EDTA solution
and cryopreserved in liquid nitrogen till further use.
13. Wharton’s Jelly derived mesenchymal stem cells
Studies have demonstrated the multipotent properties of mesenchymal stromal cells isolated
from the inner matrix of the Wharton’s Jelly derived from the umbilical cord. These cells have
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also been demonstrated to differentiate into neuronal lineage and supporting glia [11, 12].
Based on these studies, in the current trial we have attempted to understand the therapeutic
potential of WJ-MSCs in spinal cord injury.
After appropriate informed consent, a clean, healthy, straight clamped umbilical cord approx‐
imately 10 cms in length was collected in sterile normal saline bottle and transported to the
laboratory. Briefly, the umbilical cord was washed with normal saline followed by DPBS (with
0.2% of Penstrep solution) wash for 3-4 times. This was followed by quick dip in 100% ethanol
and was cleared off in DPBS. The tissue was washed free of contaminating blood with normal
saline throughout the process and cut into 2-5 mm3 pieces. Using sterile scalpel and forceps
the cord was dissected, unfolded and the exposed arteries and vein were removed and
discarded. The cord was then scrapped gently with scalpel to obtain the viscous, jelly like
substance. The obtained suspension was passed through a 100 mm cell strainer to obtain single-
cell suspension. The resultant suspension was then diluted with saline to reduce the viscosity
of the suspension. Cells were centrifuged at 1400 rpm for 10 minutes at 37°C and the pellet
was resuspended in KO-DMEM supplemented with FBS (10%), Glutamax (1%) , Penstrep
(0.5%), FGF-2 (1ng/ml) and cultured in T-75cm2 flasks at 370 C in 5% CO2 until confluent
(80-85%). Upon confluency, the cells were harvested from the flasks and transferred to 5 cell
stacks at a seeding density of 1000 cells/cm2 for 10-12 days in order to obtain the required
number of cells for the transplantation. The harvested cells were processed and frozen in
cryobags in liquid nitrogen till use.
14. Characterization
1. Immunophenotype:
This is a technique used to study the expression of cell surface antigens on the MSCs using
flow cytometry. Briefly, the cells were dissociated with 0.25% Trypsin-EDTA and resuspended
in wash buffer at a concentration of 1 × 10^6 cells/ml. 200 μL cell suspensions were incubated
in the dark for 15 min at 4°C with saturating concentrations of phycoerythrin (PE) conjugated
antibodies. The following markers were analyzed: CD34-PE, CD45-PE, CD73-PE, CD105-PE,
CD166-PE, and CD90-PE (BD Pharmingen, San Diego, CA, USA). Flow cytometry was
performed on a 5HT Guava instrument. Appropriate isotype-matched controls were used to
set the instrument parameters. Cell viability was measured using 7-amino actinomycin D (7-
AAD). Cells were identified by light scatter for 10,000 gated events and analyzed.
2. Multipotent differentiation assay
The mesenchymal properties of human stem cells isolated from various sources as described
above, were investigated using specific differentiation kits for the three different lineages i.e.,
osteogenic, adipogenic and chondrogenic (as per ISCT criteria).
Briefly, Osteoblast differentiation was induced by culturing human MSCs in KO-DMEM
supplemented with 10% FBS (Hyclone), 200 26mM Glutamax (Invitrogen), 10-8 M dexa
methasone (Sigma-Aldrich), 30 μgm/ml ascorbic acid (Sigma-Aldrich) and 10 mM β-glycero‐
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phosphate (Sigma-Aldrich Chemical Private Limited, Bangalore, Karnataka, India) for 3
weeks. Fresh medium was replenished every 3 days. Calcium accumulation was assessed by
von Kossa staining. The differentiated cells were washed with PBS and fixed with 10% formalin
for 30 min. The fixed cells were incubated with 5% AgNO3 for 60 min under ultraviolet (UV)
light and then treated with 2.5% sodium thiosulphate for 5 min. Images were captured using
an Nikon Eclipse 90i microscope (Nikon Corporation, Towa Optics, New Delhi, India;
www.nikon.com) and Image-Pro Express soft ware (Media Cybernetics Inc., Silver Spring,
MD, USA; www. mediacy.com).
To induce adipogenic differentiation, human MSCs were cultured for 21 days in KO-DMEM
supplemented with 10% FBS, 200 mM Glutamax, 1 μm dexamethasone, 0.5 mM isobutylme‐
thylxanthine, 1 μg/ml insulin and 100 μm indomethacin (from Sigma-Aldrich). Inducing
factors were fixed in 10% formalin for 20 min and 200 μl Oil Red O staining solution added
and incubated for 10 min at room temperature. The cells were rinsed five times with distilled
water. The images were captured using Nikon Eclipse 90i microscope (Nikon) and Image-Pro
Express software (Media Cybernetics).
For chondrogenic differentiation, human MSCs were cultured for 21 days using Chondrogenesis
differentiation kit (Life Technologies, USA) as per the manufacturer’s recommendations and
stained with Safranin O as specified. The images were captured using Nikon Eclipse 90i
microscope (Nikon Corporation, Towa Optics, New Delhi, India).
14.1. Karyotyping
A standard G-banding protocol was performed by analyzing more than 200 cells per sample
and reported according to the International System for Human Cytogenetic Nomenclature
(ISCN). If the cells did not fall under the set standard of the above mentioned tests, they would
not be released to the patient for transplantation was discarded appropriately.
14.2. Quality control testing
Based on the ISCT guidelines, certain quality control tests were performed on the end product
before transplantation. These include Mycoplasma (using RT-PCR based method), Endotoxin
testing by Limulus Amebocyte Lysate (LAL) method and cell surface markers like CD73, CD90,
CD105, CD166, CD34, and CD45 via flow cytometry. The positive markers (CD73, CD90,
CD105 and CD166) should be greater than 95% positive, while the negative markers (CD34
and CD45) must be less than 2% positive. 7-AAD (7-amino actinomycin D) was also analyzed
via flow cytometry to determine the cell viability.
14.3. Processing of cells for transplantation
As described above, the cells were harvested and processed for transplantation. Briefly, the
total cell count was calculated using a standard hemocytometer. The cells were washed several
times with normal saline solution and finally resuspended in saline containing 0.2% human
serum albumin. All the syringes and bottles were appropriately labeled. These were packaged
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in a sterile container and dispatched in a transportation container maintained at 22°C to the
hospital for transplantation via the shortest route.
14.4. Route of administration
1. Intrathecal administration through Lumbar Puncture (LP) method:. The pateinet was
positioned in lateral decubitous position and the part prepared. Under aseptic conditions
lumbar puncture was performed at lowest possible level usually L4-5 or L5-S1 levels. Once
clear CSF was obtained the cells were delivered into the intra thecal space gently. The
procedure was repeated as per the protocol.
2. Intra Venous – Regular intravenous infusion of cells in 50 ml saline administered into the
peripheral veins of the hand.
3. At the site of injury-either by laminectomy or image guidance
Laminectomy-was performed where ever decompression was indicated with or without
stabilization. Surgical technique includes prone position and exposure of lamina at appropriate
level under general anesthesia. Dura was opened and injured cord was inspected.
Scar  excision-In  chronic  injuries  with  glial  scar  or  neuroma  the  intervening  tissue  was
removed gently till  healthy appearing tissue was seen under high magnification.  Cavity
was decompressed.  The cells  were  injected into  the  ends  of  the  cord tissue  through an
insulin syringe. If the edges are apart a scaffold or gelfoam was used to bridge the gap.
Dura was closed water tight.  If  the cord was oedematous (acute injury) doroplasty was
performed. Additional cells were delivered into intra thecal space and Laminectomy was
closed using standard technique.
Image guidance method-In chronic complete injuries CT guided technique was used to deliver
the cells directly at the site of injury.
Clinical assessment was performed on all patients based on the parameters of the ASIA
impairment scale (American Spinal Injury Association). This was considered as the primary
measurable outcome of the clinical study.
A Complete: No motor or sensory function is preserved in the sacral segments S4-S5.
B Incomplete: Sensory but not motor function is preserved below the neurological level and
Includes the sacral segments S4-S5.
C Incomplete: Motor function is preserved below the neurological level, and more than half of key muscles below
the neurological level have a muscle grade less than 3.
D Incomplete: Motor function is preserved below the neurological level, and at least half of key muscles below the
neurological level have a muscle grade of 3 or more.
E Normal: Motor and sensory functions are normal.
Table 3. ASIA impairment scale
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14.5. Follow up schedule
At every follow-up, the patients were assessed clinically using the ASIA scale rating system
and with the Barthel’s index (BI) for degree of independence and patient rating. MRI was
performed to observe structural changes, if any.
15. Isolation and identification of mononuclear cells and mesenchymal
stem cells
15.1. Autologous BM derived MNCs
BM samples were aspirated from the patients (n=9) after getting proper consent and the
samples were processed in cGMP compliant clean room facility for the isolation of the MNCs
following the standardized protocol as described above. CD34 expression was analyzed using
PE conjugated CD34 antibody in flow cytometer and cell count was performed prior to
transplantation.
15.2. Autologous bone marrow derived MSCs
BM samples obtained from the patients (n=11) after getting proper consent were processed in
cGMP compliant clean room facility for the isolation propagation and expansion following the
standardized protocol as described above. Flow cytometry analysis revealed that cell samples
with positive markers are >95% and <2% of negative markers with >90% viability with 7AAD
staining indicating the cells were mesenchymal in nature. Multipotent characteristics, as
determined by Oil Red O stain, Von Kossa stain and Safranin O stain, respectively indicates
the cell samples undergo adipogenic, osteogenic and chondrogenic differentiation. Karyotypes
of all the cell samples were normal and no abnormalities/aberrations were found after ex vivo
propagation figure. Endotoxin test using LAL method and Mycoplasma test using RT-PCR
were found to be negative indicating the cells were safe for transplantation.
15.3. Allogenic BM derived MSCs
BM samples obtained from the donors after appropriate informed consent and the samples
were processed in cGMP compliant clean room facility for the isolation, propagation and
expansion. Stem cells thus extracted are cryopreserved as master cell bank (MCB) in liquid
nitrogen. From MCB, working cell banks (WCB) were raised in tissue culture plates until
required number of cells obtained for the infusion. The cells were then harvested and frozen
as investigational product (IP) until use. Prior to transplantation the cells were thawed and
processed further. The cell samples were found to express positive markers >95% and <2% for
negative markers, with >95% viability, when stained with 7AAD as determined by flow
cytometry indicating the Mesenchymal nature of the processed cells. Multipotent character‐
istics, as determined by Oil Red O stain, Von Kossa stain and Safranin O stain, respectively,
indicating the cell samples undergo adipogenic, osteogenic and chondrogenic differentiation.
Karyotype of all the cell samples was normal and no abnormalities/aberrations were found
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after ex vivo propagation figure. End product testing such as endotoxin test using LAL method
and Mycoplasma test using RT-PCR were found to be negative indicating the cells were safe.
15.4. Adipose tissue derived MSCs
Mesenchymal  stem  cells  isolated  from  fat  samples  received  in  a  sterile  container  after
liposuction were expanded in above mentioned conditions until the cells were confluent.
Post confluent, the cells were harvested and stored frozen in liquid nitrogen as MCB, from
which  WCB  were  raised.  IP  were  cultured  on  appropriate  tissue  culture  plates  on  re‐
quest.  Prior  to  transplantation,  in  process  test  and  end  process  test  were  done.  Flow
cytometric analysis showed that the cells express the surface markers with >95% for positive
markers (fig) and <2% for negative markers (fig) with >90%% viabilty. The cells were found
to undergo adipogenic, osteogenic and chondrogenic differentiation as determined by Oil
Red O stain, Von Kossa stain and Safranin O stain, respectively. All the samples showed
normal  karyotypes  and no  abnormalities/aberrations  were  noted  after  ex  vivo  propaga‐
tion.  A  representative  ideogram  is  illustrated  in  Figure.  The  cell  samples  tested  for
endotoxin  using  LAL  method  and  Mycoplasma  test  using  RT-PCR  were  found  to  be
negative indicating the cells were safe to be infused.
15.5. Wharton’s Jelly derived MSCs
Umbilical cords obtained postpartum in a sterile container were processed according to the
standard protocol described earlier. The cells were further up-scaled and expanded in order
to provide the required number of cells for the patient. The cultured cells were found to show
normal spindle shaped phenotype when observed (fig). Flow cytometric analysis showed that
the cells were positive with >95% for positive markers and <2% for negative markers (fig) with
>90% viability. The cells were found to undergo adipogenic, osteogenic and chondrogenic
differentiation as determined by Oil Red O stain, Von Kossa stain and Safranin O stain,
respectively. All the samples showed normal karyotypes and no abnormalities/aberrations
were noted after ex vivo propagation by standard G banding method. A representative
ideogram is illustrated in Figure. The cell samples tested for endotoxin using LAL method and
Mycoplasma test using RT-PCR were found to be negative indicating the cells were safe for
the transplantation.
16. Clinical assessment
16.1. Clinical examination and ASIA scale scoring
Clinical assessment was performed on all patients based on the parameters of the ASIA
impairment scale. This was considered as the primary measurable outcome of the clinical
study.
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16.2. Results
As per the inclusion and exclusion criteria mentioned above, 52 volunteers were recruited for
this study. This includes 8 females and 44 males between the age group 17 and 66 years.
Duration of injury varied between 15 days after injury to 20 years. All the patients were divided
into 4 groups based on the type of cells received. The details of the patients recruited for this
study are given in Tables below.
Case No. Age Sex Level of
injury
Duration of
injury
No. of
injection
Route of
infusion
1 23 M D11-D12 0 month 1 Laminectomy + IV
2 31 M D4, C6-7 7 months 1 Laminectomy + IV
3 23 M D11 4 months 1 Laminectomy + IV
4 26 F C5-C6 1 year 1 Laminectomy + IV
5 21 M C4-C5 1 year 1 Laminectomy + IV
6 26 F C5-C6 1 year 1 Laminectomy + IV
7 53 M C6-C7 3 years 1 Laminectomy + IV
8 23 M C5-C6 3 years 1 Laminectomy + IV
9 31 M C6-C7 4 years 1 Laminectomy + IV
Table 4. Group 1-Autologous Bone Marrow derived mononuclear cells (BMMNCs; n=9).
Case No. Age Sex Level ofinjury
Duration of
injury
No. of
injection
Route of
infusion
1 59 F D3-D5 7 years 1 CT Guided
2 34 M C7 6 years 1 CT Guided
3 56 M D4 14 years 1 CT Guided
4 54 M D5-D6 2 years 1 CT Guided
5 49 M D6 4 years 1 CT Guided
6 26 M D12 2 years 1 CT Guided
7 23 M C4-C6 1 years 1 CT Guided
8 31 M L1 4 years 1 CT Guided
9 42 M D12 3 years 1 CT Guided
10 28 M C5-C6 3 years 1 CT Guided
11 28 M D5-D6 5 years 1 CT Guided
Table 5. Group 2-Autologous Bone Marrow derived Mesenchymal stem cells (BMMSCs; n=11)
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Table 6: Group 3-Allogeneic BMMSCs or Adipose tissue derived MSCs (ADMSCs) or Whar‐
ton’s jelly derived MSCs (WJMSCs) (n=26)
Case No. Age Sex Level ofinjury
Duration of
injury
No. of
injection
Route of
infusion
1 19 F D4-D6 1 year 1 CT Guided
2 36 F D10 1 month 3 Intrathecal
3 27 M T12-L1 1 year 1 CT Guided
4 36 M C6-C7 2 months 1 Laminectomy + IV
5 26 M D3 3 months 1 Laminectomy + IV
6 46 M C3-C4 0 month 1 Laminectomy + IV
7 29 M Partial 1 year 3 Intrathecal
8 45 M C1-L1 1 year 1 Laminectomy + IV
9 50 F C2 1 year 1 Laminectomy + IV
10 46 F Dorsal SCI 1 year 3 Intrathecal
11 25 M D9-D10 1 year 3 Intrathecal
12 29 F D4 1 year 3 Intrathecal
13 27 M SCI 10 months 1 Laminectomy + IV
14 26 M C7-T1 3 years 3 Intrathecal
15 27 M Cervical 6 months 3 Intrathecal
16 51 M D4-D6 20 years 3 Intrathecal
(a)
Case No. Age Sex Level of injury Duration of injury No. of injection Route Of infusion
1 23 M Cervical 2 years 3 Intrathecal
2 54 M Thoracic 1 year 3 Intrathecal
3 54 M C4-C5 6 months 3 Intrathecal
4 31 M C2-D4 1 year 3 Intrathecal
(b)
Case No. Age Sex Level of injury Duration of injury No. of injection Route Of infusion
1 47 M Cervical 8 months 3 Intrathecal
2 37 M D12 4 years 3 Intrathecal
3 42 M Thoracic 3 Intrathecal
4 35 M C3-C4 0 month 3 Intrathecal
5 27 M C5-C6 6 years 3 Intrathecal
6 37 M Thoracic 13 years 3 Intrathecal
(c)
Table 6. (a): Subgroup 1: BMMSCs, (b): Subgroup 2: WJMSCs, (c): Sub group 3: ADMSCs
On an average, 2 million cells /kg bodyweight were transplanted via 3 different routes i.e.,
laminectomy, lumbar puncture, and intravenous injections. All the patients stood the proce‐
dure well, there were no postoperative complications and were discharged within a week’s
Topics in Paraplegia260
time from the hospital, indicating that there were no immediate cytotoxic effects due to
implantation of various cell types (as mentioned above) and the procedures were safe.
The ASIA rating scale did not reveal any significant changes or further worsening or deterio‐
ration in neurological or functional level pre and post stem cells therapy.
Of the total patient recruited for the study, 9 patients have shown notable clinical and func‐
tional recovery. While follow-up, one patient (G3C2; Table 4a) whose baseline report was as
follows: Motor – Upper limb-5/5, Lower limb-2/5, Sensory – Loss of sensation at D 10 and below
for all modalities, reported to be able to stand and walk with support and does swimming.
Another patient (G4C3; Table 5], at baseline with power at shoulder-grade 3/5, Power at elbow
joint-3/5 in flexion and extension and hand grip-2/5, lower limbs-grade 0/5 with generalized
wasting in all limbs and spasticity in both the lower limbs, anesthesia below C6 dermatomes
and exaggerated deep tendon reflexes in lower limbs, has shown minimal recovery.
Slight improvement in Upper Limb sensation after the first dose, was reported by one patient
(G1C5; Table 2). However at times, the patient had painful sensations.
Post therapy one patient (G4C4; Table 5) was able to feel the bladder fullness from 3rd month
of transplantation. In subsequent follow-up, the imbalance while sitting on the wheel chair has
partially improved. Also, improvement in touch and pain sensation up-to the right knee on
the right side and up to the upper thigh in the left side were noted. Bladder sensations have
improved to some extent.
Additionally two patients (G4C5; Table 5 and G3C4; Table 4c) has shown improvement in
sensation and able to sit with support.
Two patients (G3C1 and G3C3; Table 4c &4b) were able to walk with the aid of walker post
therapy. But however, the latter patient had a fall and is now back to baseline.
One patient (G3C5; Table 4c) has regained some sensation in abdomen and lower back area
and below feet. The patient can now feel stretching sensation in toes when performing exercises
and becoming more aware of bowel movements.
Out of the 52 patients treated, only 3 patients reported pain after infusion. And two patients
were lost to follow-up.
Barthel’s Index Score
Barthel’s index (BI) was performed on all patients, pre-and post-transplantation of the cells.
No significant improvement or appreciable changes were observed in the patients with long
history of injury. However, patients with less than 6 months of injury have shown improve‐
ment in the scores.
Magnetic resonance imaging (MRI) of the spinal cord before and after stem cell infusion:
No change was observed in MRI findings at baseline and post-stem cell transplantation. Also,
no adverse effects of transplantation were detected on the MRI post transplantation. Further,
no changes in cystic regions or syringomyelia, and no further external compression of the cord
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or formation of tumor-like masses in and around the injection site or along the cord, were
visualized.
17. Discussion
Spinal cord essentially is a conduit integrating relay and transmission of signals and the
functions of the body (motor, sensory and autonomic) with the higher centers (brain brainstem
& cerebellum). SCI can be devastating with lifelong disability due to its complex architecture
and compounding consequences that follows an injury. Disruption of such local integrative
networks interrupts ascending and descending input and outputs resulting in dysfunction of
motor, sensory, autonomic and dysregulation of various reflexes in the body. Majority are in
the age range of 16-35. Damage to the spinal cord progresses rapidly in stages. In the last two
decades, researchers have made their efforts to understand this complex pathobiology from
several animal studies [6]. Ischemia,Scarring, cavitation, wallarian degeneration, axonal die
back, excitotoxins, inflammation and several complex cellular and molecular changes are
known to influence recovery of such injury. Several medical (pharmacological and others) and
surgical attempts did not influence any substantial positive outcomes. Hence the attention was
turned towards neurotrophic factors and cell based treatments. As a result spontaneous
neurological recovery has been reported only in 6-13% of patients with only 2% gaining any
functional recovery. [113-116].
Cell death is often rapid after SCI. The adult spinal cord harbors endogenous stem/progenitor
cells, collectively referred to as Neural Progenitor Cells (NPCs) that might be responsible for
normal turnover of the cells and repair process. Several studies have confirmed that new cells
are born around the central canal from the ependymal precursors [1].However, the prolifera‐
tive activity of endogenous NPCs is too limited and grossly inadequate to support spontaneous
repair after SCI. Hence various cell transplantation strategies have been adopted in models of
SCI such as embryonic stem cells, Wharton’s jelly, adult neural stem cells, bone marrow and
adipose tissue derived Mesenchymal stem cells [13]. They are currently being studied as
potential sources of neurons, glial cells or neurotrophic factors. Transplantation of these cells
to create or regenerate spinal cord as an alternative therapy has generated lot of interest. This
study clearly documents the feasibility of such cell replacement strategies [14].
Several studies have reported several protocols different timings and type of cells [117-120].
We have studied autologous BMMNCs, BMMSCs (autologous and allogenic), WJMSCs and
ADMSCs (allogenic) have been used to study their therapeutic potential in spinal cord injury.
Those who received autologous BMMNCs showed only minimal improvement. The reason
may be due to variations in age; extent, duration of injury; and variance in cell quantity and
quality.
Nevertheless, autologous BMMSCs had shown good improvement, the concern with the
transplantation is the availability of cells in time and other problems as mentioned above.
Recently, allogenic MSCs from sources like Bone marrow, Adipose tissue and Wharton’s jelly
shown to have attracted many, to use it as source for treatment and conducting trials on them.
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The advantages of allogenic cells over autologous cells for transplantation may be that, they
are readily available with defined cell quality and quantity. This makes allogenic stem cells, a
good choice to make extensive research on the feasibility in other therapeutic interventions.
In addition it offers an opportunity to use the cells as early as possible. It has been the obser‐
vation that early intervention within few days has yielded marginally better results suggesting
an optimal temporal window for cell mediated therapy. [121]. several studies have indicated
better results with early intervention and acute injury. [122, 123, 121]. The preclinical literature
also has suggested that there is an earlier window for the optimization of cell therapies [125,
124]. Now its well known that these cells do HOME at the required site. Homing could be
mediated by the ongoing cell reactions, products of cell death or inflammation or some chemo
attractants. We believe timing of delivery of cells is crucial for these cells to impregnate in large
numbers.In delayed or chronic injuries cell reach may be poor and once gliosis sets in cell
penetration may be difficult. In addition spinalcord –csf barrier doesn’t allow cell migration
into the parenchyma.
The strategy to cord injury is twofold-Initial control of damage and minimizing secondary
deleterious effects, and later promotion of recovery. Cell therapy can play a role in both
provided they were given at the right time.. However there is no sufficient data to indicate the
exact time of maximizing the benefit. In general those who are likely to be benefited must be
treated before the molecular mechanisms cause the irreparable damage. [5] The drawback of
our study is timing could not be controlled since they were inducted as and when they came
to our clinical service. In addition its difficult to have clinical controls.
A  canine  study  from  South  Korea  2009  used  autologous  and  allogenic  cells.  Though
autologous BM-MSCs had better  results  than allogenic  both showed better  results  com‐
pared to controls [126]
Literature shows several routes of administration like intra arterial, intravenous, intra thecal
and direct injections to the injured cord. Intra thecal injection was most frequently used
method. [121]. Our study also demonstrates that administration of MSCs via multiple routes
such as laminectomy, lumbar puncture and intravenous delivery, are feasible and safe. Though
direct injection into the cord appears logical,the apprehension of enhancing the injury always
exists. In our opinion it is invasive and should be reserved for those where decompression or
stabilization is indicated and most suitable in chronic complete inuries.. Saberi et al [119]
reported no serious adverse effect after intraparenchymal injections. They also reported
transient low grade fever with nausea, vomiting and headache. But we did not encounter such
complications in our series. The use of scaffold is complimentary and may have positive
influence. [110]. In chronic injuries widening of anatomical gap between the functional tissues
of the cord is a challenge and a possible reason for poor outcomes. Degeneration makes this
anatomical and functional gap wider with time. Often this gap gets replaced by glial scar which
becomes a physical barrier preventing cellular penetration,regeneration and migration.
Scaffolds can act as an anatomical substrate on which these cells can grow and connect the
physiological ends.
It appears that the cytokines and bio active molecules secreted by these cells play a significant
role in acute as well as sub acute phases. Therefore it is essential to retain the cells at the required
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area in sufficient numbers. We have included only complete injuries so as to remove the bias
of spontaneous recovery. Based on our results and the positive role of anatomical continuity
we feel partial injuries shall definitely benefit more. Cell therapy can augment the spontaneous
recovery either by promotion or reducing the derogatory inhibitory influences.
In our findings delivery through lumbar puncture is simple and equally effective [111-112].
But cell survival in CSF and their functionality need to be enhanced. Retaining large number
of cells at the site of injury is also a challenge. We did not encounter any adverse reaction or
infection. After lumbar puncture majority had low pressure headaches which were treated
with fluid therapy and analgesics effectively. Kishk et al reported neuropathic pain in 56% of
their patients following intrathecal injection which was not noticed in our series.
Though the results of animal experiments are enticing the overall translation into clinical
benefit is minimal and quite disappointing. Irrespective of site of injury, route of administra‐
tion and type of cell the clinical recovery is very minimal and only less than 1/3rd showed signs
of recovery. Useful functional recovery was seen only in 7-9%. This is rather disappointing.
Therefore it appears that even cell therapy has its limitations. But there has been definite
evidence of clinical recovery in few and are useful to understand the role of cell therapy. It
appears we are somewhere closer to some success yet needs understanding to augment these
benefits. Young age, focal segmental injury and early intervention seem to benefit or compli‐
ment recovery. Though all our patients expressed subjective well being, ability to sit for longer
periods and actively participation in physical excercises following cell therapy could be
mediated by cytokines and growth factors. In addition trunk muscles just above the site of
injury showed definite clinical improvement. This could explain the need of anatomical
integrity for recovery and also their enhanced ability to sit longer. In the distal segment sensory,
long tracts and bladder have shown signs of recovery in many, but few had clinically useful
benefit. Motor recovery is the most difficult to achieve. Possibly due to loss of trophic influence
from higher centers, vascularity which leads to loss of anterior horn cells. Presently available
imaging and electro physiological methods are not sensitive enough to detect or monitor
regeneration in spinal cord. Those who recovered could be potential partial injuries (anatom‐
ical continuity) although behaved as complete injuries clinically.. This could be the possible
reason of useful clinical recovery observed in our study. Presently we feel role of cell therapy
is only complimentary. MSCs are known for immunomodulation and once administered in
the right time may help in minimiging neural inflammation and immune mediated damage.
Early intervention might reduce gliosis and promote recovery through secretion of cytokines,
bioactive molecules and growth factors. These cells also known for angiogenesis hence benefit
by revascularization of spinal cord. Lastly the role of effective activation native progenitor cells
to come the rescue of adequate repair needs further exploration. Preservation and promotion
of recovery of ant horn cells and reestablishing neuronal functional circuits should be the focus.
Going forward, SCI appears to be the most difficult clinical challenge today. Our understand‐
ing of its pathobiology is not complete. The challenges are local (site of injury), peripheral
(body below the site of injury) and central (higher centers). The future strategy need to target
all the three. Augmenting central influences; sustaining muscles with proper neurotization,
rehabilitation, promoting recovery and regeneration at the site seems to be the goal. Several
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methods and mechanisms alone or in combination need to put in place.Rehabilitation does
play a significant role in those with clinical recovery. We speculate that combination of rehab
and regeneration may be better. The local neuronal circuits within the segments of the cord
must be sustained to retain the integrity of the reflex arc. This appears complex and needs
further experimental and clinical data to understand the underlying mechanisms.
18. Conclusion
In conclusion, the surge of research activities in the cell therapies for SCI has yielded only
mixed results. While the pre clinical studies are quite promising it is difficult to reproduce
similar results in the clinical scenario.. Knowing the mechanisms involved stem cells seems to
have specific role and prospects for future studies. Future direction should focus on enhancing
the benefits of cell therapy by combination of methods systematically addressing the chal‐
lenges involved. Our study documents safety and influence on recovery to some extent paves
the way for further preclinical and clinical studies with proper design. Such larger clinical
studies only can overcome the present diversity in methods and outcomes.
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